Geron Restructuring Sours Investors As Company Bets On Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
You may also be interested in...
Geron CEO: Getting Imetelstat Data Wanted By FDA Will Be “Difficult”
Concerned about chronic liver injury, FDA halts development of Geron’s telomerase inhibitor imetelstat, the only drug left standing in Geron’s pipeline, and requests data for patients who discontinued treatment in Geron-sponsored plus non-Geron studies.
For Cutting-Edge Stem Cell Work, California Billions Still Unmatched
California’s stem cell agency still has nearly two billion dollars to grant. But with recent stem cell breakthroughs slow to translate, will venture backers and drug firms help build the ecosystem California citizens imagined in 2004 when they voted to make the state a beacon for the science?
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.